Group 1 - The Hong Kong Innovation Drug ETF (159570) experienced a 1.5% decline, marking its fourth consecutive day of decrease, with a trading volume exceeding 1.3 billion yuan [1] - The ETF has attracted a net inflow of over 6 million yuan during the day and has accumulated over 740 million yuan in the last 10 days, with a total size exceeding 23.6 billion yuan as of December 2 [1] - Major weighted stocks in the ETF, such as 3SBio, Innovent Biologics, and China Biologic Products, saw declines of over 2%, while others like CSPC Pharmaceutical and BeiGene dropped over 1% [2][3] Group 2 - The upcoming ASH conference is expected to reveal key data in the hematology field, which may catalyze the valuation recovery of related pipelines, particularly for companies with differentiated advantages in oncology, autoimmune, and rare disease products [5] - The Chinese innovative drug industry has shown significant growth, with the number of clinical trials increasing from 1,473 in 2020 to 2,539 in 2024, reflecting a compound annual growth rate of over 15% [6][9] - Chinese pharmaceutical companies are becoming increasingly prominent in global research, contributing 27% in oncology and 19% in autoimmune fields, with significant positions in ADC targets such as HER2 and TROP2 [9]

今天分享的是：自免行业报告(二)：PROTAC实现"0-1"突破，看好自免口服破局潜力 报告共计：43页 PROTAC技术发展与自免领域应用潜力总结 本报告聚焦PROTAC（蛋白降解靶向嵌合体）技术，深入分析其机制优势、行业现状及在自身免疫性疾病（自免）领域的应用潜力。 PROTAC通过双功能小分子将目标蛋白与细胞内E3泛素连接酶拉近，借助泛素蛋白酶体系统降解目标蛋白，具备独特优势：可靶向传统小分子抑制剂难以作 用的"不可成药"蛋白，能克服靶点突变或表达上调导致的耐药性，且因催化特性具有高选择性和低剂量优势，除肿瘤外，在自免疾病等领域展现出广阔应用 前景。目前约80%的临床PROTAC针对癌症，技术整体处于早期阶段，分子结构设计仍有较大迭代空间。 与竞争激烈的肿瘤领域不同，自免口服药物市场尚处蓝海，尤其皮肤科药物市场潜力巨大。2023年银屑病整体市场规模达270亿美金，口服药物仅占9%，据 预测，2034年左右其市占率有望提升至33%。自免领域仍有大量未被满足的需求，约50%-70%的银屑病/IBD患者未接受先进疗法，且75%的注射性药物使用 者愿意切换至口服药物，而PROTAC兼具类生物制剂的疗效与安全性， ...

12月3日，港股创新药板块延续调整态势，龙头股集体飘绿，百济神州、信达生物、石药集团齐跌逾 1%，中国生物制药、三生制药跌超2%。 港股通创新药ETF（520880）超7成仓位押注创新药龙头股，持续水下震荡，截至发稿跌逾1%，连续第 4日下跌。不过场内延续宽幅溢价，显示买盘资金相对强势。 | | | 分时 多日 1分 5分 15分 30分 · | | | F9 發前盘后 發加 九越 画坊 丁具 @ (2) | | | 港股通创新药ETF O | | 520880 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 520880[種腔通创新药ETF] 13:19 价 0.553 涨跌 -0.007(-1.25%) 均价 0.556 成交量 | | | | | | | | | 0.570 | | | | | | | | 05 | | -0.007 -1.25% | | 0,567 | | | | | | | 1.2496 | SSE CNY 13:19:54 文明中 | | # ■ Z 版 O+1 | | | ...

投创新药，首选同类最大港股通创新药ETF（520880）及其场外联接基金（025221），标的指数恒生港 股通创新药精选指数具备三大独特优势： 1、纯粹，全面。不含CXO，纯正创新药！全面覆盖创新药研发类公司。 2、龙头占比大。前十大创新药龙头权重超72%，表征创新药硬核力量。 3、风险更可控。对流动性较差的成份股强制降权，有力管控尾部风险。 | | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股权重高达72.57%，龙头优势显著 | | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 百济神州 | 11.51 | 3,070 | | 1801.HK | 信达生物 | 10.19 | 1,613 | | 1177.HK | 中国生物制药 | 9.47 | 1,323 | | 9926.HK | 康方生物 | 66'8 | 1,132 | | 1093.HK | 石药编团 | 8.39 | 911 | | 1530.HK | 三生制药 | 8.32 | 760 | | 3692.HK | ...

大消费表现不错，截至目前上涨0.65%，其中比亚迪股份大涨3.42%，波司登上涨2.2%，金沙江中国上 涨2.15%，美高梅、复星国际、美的集团、海底捞等超10只个股涨幅在1%上方。 恒生医疗开盘后直线跳水，随后探底回升，截至目前下跌0.3%。其中三生制药大跌3.79%，京东健康下 跌2.36%，百济神州、药明康德、康方生物、石药集团等股均小幅下跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数开盘后直线拉升，随后维持在高位配置，截至目前上涨0.74%。恒生互联网涨幅居前，科技、 大消费紧随其后，恒生医疗和银行逆势回撤。 互联网跌幅高开后探底回升，截至目前上涨0.56%。快手大涨4.1%，阿里巴巴上涨2.78%，网易上涨 1.44%，百度集团、腾讯控股等均小幅上涨；美团、哔哩哔哩、地平线机器人等股逆势回撤。 ...

Core Insights - In 2025, China's pharmaceutical and healthcare industry enters a critical phase driven by "innovation deepening + global breakthrough," with emerging therapies like small nucleic acids, PROTAC, and CGT accelerating from clinical validation to commercialization [2][34] - The reports from the top ten Chinese securities firms provide authoritative insights into technological iterations, industry trends, and globalization strategies, serving as a guide for industry practitioners and investors [2][34] Group 1: Small Nucleic Acids - 2025 is a pivotal year for small nucleic acid drugs, driven by technological breakthroughs and expanding indications from rare diseases to chronic diseases like hyperlipidemia and hypertension [4][36] - The small nucleic acid sector is expected to see a surge in catalysts, including the commercialization of major products like Novartis' Inclisiran and the approval of Alnylam's Vutrisiran and Fitusiran [5][37] - The market for small nucleic acids is projected to reach approximately $30 billion, with significant growth anticipated in CNS diseases [10][42] Group 2: Brain-Computer Interface - The brain-computer interface industry is accelerating innovation with three main technical paths: invasive, semi-invasive, and non-invasive, each with distinct advantages and challenges [7][39] - The global brain-computer interface market is expected to reach approximately $2.6 billion by 2024, with a CAGR of about 13% from 2023 to 2027 [7][39] Group 3: PROTAC - PROTACs are gaining traction as targeted protein degradation drugs, with advantages such as high oral bioavailability and broad target range, making them popular in oncology and autoimmune disease research [19][51] - The first BTK PROTAC has entered Phase III trials, showcasing promising efficacy and safety data [19][51] Group 4: Chinese Innovative Drugs - Chinese innovative drugs are entering a "DeepSeek" moment, with domestic companies increasingly recognized overseas, and the number of license-out projects surpassing license-in projects for the first time in 2023 [16][48] - The market for innovative drugs in China is expected to exceed 2 trillion RMB by 2030, with a CAGR of 24.1% [29][63] Group 5: Peripheral Intervention Industry - The peripheral intervention industry is experiencing rapid growth, with a significant patient base and low treatment penetration compared to international standards [25][57] - The market for peripheral artery interventions is projected to grow at a CAGR of 15.6% from 2021 to 2030, while peripheral venous interventions may see a CAGR of 29.3% [25][57] Group 6: Weight Loss and Diabetes Treatment - The market for GLP-1RA drugs, such as semaglutide and tirzepatide, is expected to exceed $150 billion by 2031, with significant business development opportunities emerging for domestic companies [26][58] - Multi-target drug development is anticipated to overcome the limitations of single-target therapies, enhancing efficacy in weight loss and metabolic health [26][58]

Core Insights - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) experienced a net redemption of 2.867 million yuan on December 1, ranking 15th out of 198 in cross-border ETF net outflows [1] - As of December 1, the fund's latest size is 5.56 billion yuan, down from 5.59 billion yuan the previous day, with a net outflow accounting for 0.05% of the previous day's size [1] - Over the past 5 days, the fund faced a net redemption of 4.3125 million yuan, ranking 53rd out of 198 in cross-border ETF net outflows [1] - In the last 10 days, the fund saw a net subscription of 129 million yuan, ranking 34th out of 198 in cross-border ETF net inflows [1] - Over the past 20 days, the fund had a net subscription of 251 million yuan, ranking 36th out of 198 in cross-border ETF net inflows [1] Fund Details - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) was established on March 26, 2025, with an annual management fee of 0.40% and a custody fee of 0.07% [1] - The fund tracks the Hong Kong Stock Connect Innovative Drug Index (987018) [1] - As of December 1, the fund's total shares are 3.865 billion, with a total size of 5.56 billion yuan [1] Liquidity and Performance - As of December 1, the fund's cumulative trading amount over the last 20 trading days is 13.981 billion yuan, with an average daily trading amount of 699 million yuan [2] - The current fund managers are Liu Weilin and Jiao Wenlong, with returns of 43.85% and 63.95% respectively since their management began [2] Top Holdings - The fund's top holdings include: - 百济神州 (10.84%, 314.54 million shares, 589 million yuan) - 康方生物 (10.77%, 454.20 million shares, 586 million yuan) - 信达生物 (10.43%, 644.10 million shares, 567 million yuan) - 中国生物制药 (9.82%, 7184.50 million shares, 534 million yuan) - 石药集团 (7.72%, 4908.40 million shares, 420 million yuan) - 三生制药 (7.41%, 1469.60 million shares, 403 million yuan) - 翰森制药 (5.50%, 908.20 million shares, 299 million yuan) - 科伦博泰生物-B (3.55%, 41.14 million shares, 193 million yuan) - 再鼎医药 (2.79%, 621.62 million shares, 151 million yuan) [2] Comparative Analysis - Other ETFs tracking the Hong Kong Stock Connect Innovative Drug Index include: - 汇添富国证港股通创新药ETF (159570) with a size of 23.978 billion yuan and a recent average daily trading amount of 2.652 billion yuan [2] - 港股创新药ETF (159567) with a size of 8.460 billion yuan and a recent average daily trading amount of 1.457 billion yuan [2] - 南方国证港股通创新药ETF (159297) with a size of 1.459 billion yuan and a recent average daily trading amount of 0.115 billion yuan [2] - 鹏华国证港股通创新药ETF (159286) with a size of 0.607 billion yuan and a recent average daily trading amount of 0.088 billion yuan [2]

恒生银行高开低走后探底回升，截至收盘上涨0.36%。其中重庆农村商业银行大涨3.18%，青岛银行上 涨2.27%，重庆银行、渣打银行、浙商银行等近10只个股涨幅在1%上方；光大银行逆势大跌3.16%，邮 储银行下跌2.55%。 恒生医疗相对偏弱，深V反转后小涨0.06%。其中京东健康大涨3.93%，药明生物、三生制药、药明康德 等股涨幅均在1%上方；康方生物、中国生物、石药集团等股逆势收跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数冲高回落后全天维持在中轴上方窄幅盘整，截止收盘上涨0.67%。互联网涨幅居前，科技、银 行紧随其后；医疗、大消费相对偏弱。 互联网小幅低开后直线拉升，随后全天维持在中轴上方窄幅盘整，截止收盘上涨0.75%。其中网易大涨 3.93%，阿里巴巴上涨2.24%，地平线机器人、百度集团、腾讯控股等多股涨幅均在1%上方。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 石藥集團有限公司 | | | 呈交日期: | 2025年12月1日 | | | I. 法定/註冊股本變動 | 不適用 | | II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01093 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 11,522,451,732 | | 0 | | 11,522,451,732 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 11,522 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [2]. Core Insights - The third-generation EGFR TKI has become the first-line standard therapy for advanced EGFR mutation NSCLC, significantly extending median progression-free survival (mPFS) to 18.9-22.1 months compared to earlier generations [4][24]. - The domestic EGFR TKI market is expected to exceed 20 billion CNY in 2024, with third-generation EGFR TKIs accounting for 88% of the market share [4][30]. - There is an urgent need to address resistance mechanisms following third-generation EGFR TKI treatment, with ongoing exploration of fourth-generation TKIs, bispecific antibodies, and antibody-drug conjugates (ADCs) [5][32]. Summary by Sections 1. High Incidence of Lung Cancer in China - Lung cancer is the most common malignant tumor globally, with approximately 2.6 million new cases expected in 2024, including about 1.15 million in China [8]. - Non-small cell lung cancer (NSCLC) accounts for around 85% of lung cancer cases, with adenocarcinoma and squamous cell carcinoma being the most prevalent subtypes [8]. 2. Third-Generation EGFR TKI as First-Line Therapy - The third-generation EGFR TKI has established itself as the first-line treatment for advanced EGFR mutation NSCLC, with significant improvements in mPFS compared to first and second generations [4][16][24]. - The report highlights the efficacy of third-generation TKIs in overcoming common mutations and their favorable safety profile [4][24]. 3. Exploration of Resistance Mechanisms - The report discusses the complexity of resistance mechanisms to third-generation EGFR TKIs, including both EGFR-dependent and independent pathways [5][32]. - Current research focuses on developing fourth-generation TKIs targeting specific mutations and exploring combination therapies with bispecific antibodies and ADCs [5][32][39]. 4. Investment Recommendations - The report emphasizes the growth potential of third-generation EGFR TKIs and suggests monitoring companies like Hansoh Pharma and Eli Lilly for market penetration and sales growth [51]. - It also highlights the progress of ADCs and bispecific antibodies in clinical trials, indicating a robust pipeline for future treatments [51][52].